Intellia Therapeutics stockholders approve doubling of authorized shares to 240M

Intellia Therapeutics, Inc.

Stockholders approved amendment to increase authorized common shares from 120M to 240M.
Three Class I directors elected: Muna Bhanji, John F. Crowley, Jesse Goodman.
Deloitte & Touche ratified as independent auditor for fiscal year 2023.
Advisory say-on-pay vote approved with 65.8M for, 1.2M against.
Amendment filed with Delaware Secretary of State on June 14, 2023.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Intellia Therapeutics, Inc.: Increased authorized shares of common stock from 120,000,000 to 240,000,000 (effective 2023-06-14).

Change: charter amendment
Effective: 2023-06-14

Exact text from the filing

On June 14, 2023, Intellia Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Company’s Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 120,000,000 to 240,000,000.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Intellia Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-14 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

The stockholders of the Company approved, on an advisory basis, the compensation of the named executive officers.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Intellia Therapeutics, Inc. shareholders approved Amendment to Certificate of Incorporation to increase authorized shares from 120,000,000 to 240,000,000 at the 2023-06-14 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

The stockholders of the Company approved and adopted an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 120,000,000 to 240,000,000.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Intellia Therapeutics, Inc. shareholders approved Election of Class I Directors at the 2023-06-14 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

The stockholders of the Company elected Muna Bhanji, R.Ph., John F. Crowley and Jesse Goodman, M.D., M.P.H. as class I directors, for a three-year term ending at the annual meeting of stockholders to be held in 2026 and until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Intellia Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-06-14 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Browse all governance changes →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-028611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.